Results 131 to 140 of about 36,256 (261)

Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives

Life
Durvalumab is an IgG1 monoclonal antibody that has efficacy in many advanced-stage cancers, especially in small-cell lung cancer. The efficacy of durvalumab can be enhanced by chemotherapy.
Gyula Laszlo Fekete, Laszlo Barna Iantovics, Júlia Edit Fekete, Laszlo Fekete   +3 more
doaj   +1 more source

Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Chronic inflammation fuels tumorigenesis via “internal drivers” and “external attractions.” Targeting these core mechanisms with combined therapies/novel deliveries enables precise, potent anti‐inflammatory–antitumor treatment. ABSTRACT Inflammation is a core pathological factor regulating tumor initiation, progression, and therapeutic resistance, and ...
Xiaodie Liu, Ziyuan Wang, Huirong Zhu, Yicun Han, Qing Ji   +4 more
wiley   +1 more source

Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec’s University teaching hospitals

Frontiers in Oncology
IntroductionConsolidation durvalumab post chemo-radiotherapy (CRT) has been demonstrated to improve survival in locally advanced non-small-cell lung cancer (NSCLC).
Valérie Labrie, Judith Lefebvre, Catherine Labbé, Kevin Jao, Mandy Malick, Serge Simard, Nicole Bouchard   +6 more
doaj   +1 more source

Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown [PDF]

, 2023
Nabendu Pore, Song Wu, Nathan Standifer, Maria Jure‐Kunkel, Melissa de los Reyes, Yashaswi Shrestha, Rebecca Halpin, Raymond Rothstein, Kathy Mulgrew, Stephen Blackmore, Philip Martin, John Meekin, Matthew Griffin, Ina Bisha, Theresa A. Proia, Ricardo J. Miragaia, Ronald Herbst, Ashok Gupta, Shaad E. Abdullah, Rajiv Raja, Melanie M. Frigault, J. Carl Barrett, Phillip A. Dennis, Maria Libera Ascierto, Michael D. Oberst   +24 more
openalex   +1 more source

Long‐Term Follow‐Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial

The Prostate, Volume 86, Issue 3, Page 365-371, February 15, 2026.
ABSTRACT Introduction Neoadjuvant intense androgen deprivation therapy (ADT) with androgen receptor signaling inhibitors (ARSIs) has shown pathologic complete responses (pCR) in prostate cancer (PCa), but long‐term survival outcomes remain unclear. This study evaluates the durability of response following neoadjuvant ADT plus enzalutamide before robot ...
Braden Millan, Nikhil Pramod, Ruben Blachman‐Braun, Jaskirat Saini, Lauren Loebach, Milan Patel, Sandeep Gurram, Baris Turkbey, Fatima Karzai, Peter A. Pinto   +9 more
wiley   +1 more source

Un raig de llum pels pacients amb el càncer més mortífer [PDF]

, 2016
Premis Pharmanews-Fedefarma 2016De tots els tipus de càncer que hi ha, el de pulmó és el que causa més morts a l’any en tot el món. Hi ha diferents teràpies, però recentment la immunoteràpia s’ha potenciat considerablement després del descobriment d ...
Cama Gibernau, Elisenda
core  

Anti‐PD‐(L)1 Antibodies: Insights From QSP‐Based Meta‐Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Checkpoint inhibitors that target PD‐1 or PD‐L1 have had a profound effect in a variety of cancers, both as a single therapy and in combinations. Meta‐analyses suggest that monoclonal antibodies (mAbs) targeting PD‐1 may yield better survival outcomes compared to anti‐PD‐L1 mAbs, however these conclusions are limited by a lack of direct ...
Carter L. Johnson, Deborah A. Flusberg, Sarah A. Head, David Flowers, Andrew Matteson, Diana H. Marcantonio, John M. Burke, Joshua F. Apgar, Georgi I. Kapitanov   +8 more
wiley   +1 more source

Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R

Cancer Treatment and Research Communications
MicroAbstract: Australian subset of the multicentric PACIFIC-R study (NCT03798535) in patients with unresectable, stage III non-small cell lung cancer without progression following chemoradiotherapy, found a median progression-free survival of 22.4 ...
Ben Markman, Steven Kao, Nick Pavlakis, Victoria Bray, Leisl Packer, Shankar Siva   +5 more
doaj   +1 more source

Treatment‐Related and Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitor‐Based Combination Therapies for Breast Cancer: A Systematic Review and Meta‐Analysis

Thoracic Cancer, Volume 17, Issue 3, February 2026.
This systematic review and meta‐analysis (100 trials, 9192 patients) clarifies breast cancer ICI‐based combination toxicity hierarchies. ICI‐ADC has higher grade ≥ 3 TRAEs; ICI‐mTKI has the worst irAEs, while ICI‐PARPi/HER2‐targeted combinations present the lowest risks.
Yunwei Lu, Huan Li, Ke Li, Yiting Chen, Shu Wang   +4 more
wiley   +1 more source

Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer. [PDF]

, 2017
Peters, S., Rizvi, N.A.
core   +1 more source